Form D — Solve Therapeutics, Inc.
0001231919-25-000548 · filed Nov 25, 2025
Figures are issuer-reported and describe stored filings. Data coverage and methodology.
Check this disclosure on SEC EDGAR · More Biotechnology filings
Offering
- Industry
- Biotechnology
- Exemptions
- Rule 506(b)
- Reported offering amount
- $120,535,618
- Reported amount sold
- $48,214,232
- Minimum investment
- $0
- Investors
- —
- Sales commission
- —
- Finders' fees
- —
Issuer
- Name
- Solve Therapeutics, Inc.
- CIK
- 1905252
- Entity
- Corporation
- Jurisdiction
- DELAWARE
- Year incorporated
- 2021
- Address
- 1025 ALAMEDA DE LAS PULGAS, SUITE 122
BELMONT, California 94002 - Phone
- (858) 357-4137
Related persons
May not be accurate — issuers self-report this list and the SEC does not verify it. Cross-check the original SEC EDGAR filing if accuracy matters.
-
David Johnson · Executive OfficerBelmont, California Find on LinkedIn ↗
-
Peter Colabuono · DirectorBelmont, California Find on LinkedIn ↗
-
Alan Colowick · DirectorBelmont, California Find on LinkedIn ↗
-
Langdon Miller · Executive OfficerBelmont, California Find on LinkedIn ↗
-
Jason Pitts · DirectorBelmont, California Find on LinkedIn ↗
-
Clayton D. Knox · Executive OfficerBelmont, California Find on LinkedIn ↗
-
Daniel McHugh · DirectorBelmont, California Find on LinkedIn ↗
-
Robert Mittendorff · DirectorBelmont, California Find on LinkedIn ↗
View the original filing on SEC EDGAR ↗